Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients

Background: Eculizumab blocks the lytic complement pathway by inhibiting C5 and has become the standard of care for certain complement-mediated diseases. Previously, we have shown that strong complement activation in vitro overrides the C5 inhibition by Eculizumab, which accounts for residual termin...

Descripción completa

Detalles Bibliográficos
Autores principales: Harder, Markus J., Höchsmann, Britta, Dopler, Arthur, Anliker, Markus, Weinstock, Christof, Skerra, Arne, Simmet, Thomas, Schrezenmeier, Hubert, Schmidt, Christoph Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657537/
https://www.ncbi.nlm.nih.gov/pubmed/31379839
http://dx.doi.org/10.3389/fimmu.2019.01639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657537/
https://www.ncbi.nlm.nih.gov/pubmed/31379839
http://dx.doi.org/10.3389/fimmu.2019.01639

Ejemplares similares